Satellos Bioscience, Inc. (MSLE) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$6.56

From 52W high−49.96%

Volume7575.00

Market cap$138.12M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$6.56

From 52W high

−49.96%

Volume

7575.00

Market cap

$138.12M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.2x

P/E (TTM)

—

RSI (14)

42.5

MomentumView details →

1D Return

+2.20%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−57.34%

ROA (TTM)

−52.23%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−23.08%

FCF YoY

−42.34%

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−79.01%

MomentumView details →

1D Return

+2.20%

YTD Return

—

1Y Return

—

RSI (14)

42.5

vs 50D SMA

−17.34%

vs 200D SMA

−20.94%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

11.22x

Quick Ratio

11.22x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.56

EPS Surprise

−9.73%

Beats (12Q)

0/12

Next Q EPS Est

−$0.64

Avg Surprise (4Q)

−13.84%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−34.31M

Op. CF (TTM)

−28.67M

Next earningsNov 13, 2026 →

Latest newsMore news →

Satellos Bioscience Inc. reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy.119d ago

The U.S. Food and Drug Administration granted Fast Track designation to Satellos Bioscience's drug candidate SAT-3247 for Duchenne muscular dystrophy.128d ago

Similar companies

LifeMD, Inc.LFMD Retension Pharmaceuticals Inc.RTSN Tycoon Group Holdings Limited03390.HK Kingworld Medicines Group Limited01110.HK High Tide Inc.HITI Clinuvel Pharmaceuticals Ltd.CUVL Find similar companies →

Latest newsMore news →

Satellos Bioscience Inc. reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy.119d ago The U.S. Food and Drug Administration granted Fast Track designation to Satellos Bioscience's drug candidate SAT-3247 for Duchenne muscular dystrophy.128d ago